Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881361 · ClinicalTrials.gov registry record · Phase 2
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 756
- Enrollment target
- 20
- Study locations
NCT00881361 is a Phase 2 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 756 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00881361, a Phase 2 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 756 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying surgery to remove the sentinel lymph node and axillary lymph nodes after chemotherapy in treating women with stage II, stage IIIA, or stage IIIB breast cancer.
Conditions Studied
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG systemic chemotherapy
- PROCEDURE axillary lymph node dissection
- PROCEDURE neoadjuvant therapy
- PROCEDURE sentinel lymph node biopsy
Study Locations (20)
California
- East Bay Radiation Oncology Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Cancer Care Center at John Muir Health - Concord Campus - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Valley Medical Oncology - Fremont
- Todd Cancer Institute at Long Beach Memorial Medical Center - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- Community Hospital of the Monterey Peninsula Comprehensive Cancer Center - Monterey
- Camino Medical Group - Treatment Center - Mountain View
- El Camino Hospital Cancer Center - Mountain View
- Highland General Hospital - Oakland
- Bay Area Breast Surgeons, Incorporated - Oakland
- CCOP - Bay Area Tumor Institute - Oakland
- Larry G Strieff MD Medical Corporation - Oakland
- Tom K Lee, Incorporated - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Alaska
- Providence Cancer Center - Anchorage
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2009-07 |
| Est. Completion | 2023-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881361
The ClinicalTrials.gov registry entry for NCT00881361 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 756 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which therapeutic conventional surgery is the first listed.
NCT00881361 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00881361 about?
NCT00881361 is a clinical study titled "Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This...
What is the current status of trial NCT00881361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 756 participants. The study started on 2009-07. Estimated completion is 2023-04-15.
What conditions does trial NCT00881361 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00881361?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), systemic chemotherapy (DRUG), axillary lymph node dissection (PROCEDURE), neoadjuvant therapy (PROCEDURE), sentinel lymph node biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00881361?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00881361 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.